BIOPLUS ACQUISITION CORP. Financial Statements (2025 and earlier)

Company Profile

Business Address 260 MADISON AVENUE, SUITE 800
NEW YORK, NY 10016
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,371140,302107,073294,693442,722 
Cash and cash equivalent35,371140,302107,073294,693442,722 
Prepaid expense411,773408,461521,483420,845374,417 
Total current assets:447,144548,763628,556715,538817,139 
Noncurrent Assets
Prepaid expense    156,464308,472 
Asset, held-in-trust240,372,461237,775,823235,883,906234,934,407234,654,062 
Total noncurrent assets:240,372,461237,775,823235,883,906235,090,871234,962,534 
TOTAL ASSETS:240,819,605238,324,586236,512,462235,806,409235,779,673 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities226,130263,150288,453241,531198,545 
Accrued liabilities226,130263,150288,453241,531198,545 
Debt      
Due to related parties474,400263,725  3,671 
Other undisclosed current liabilities    37,500 
Total current liabilities:700,530526,875288,453241,531239,716 
Noncurrent Liabilities
Other undisclosed noncurrent liabilities14,800,00014,800,00014,800,00014,800,00014,800,000 
Total noncurrent liabilities:14,800,00014,800,00014,800,00014,800,00014,800,000 
Total liabilities:15,500,53015,326,87515,088,45315,041,53115,039,716 
Temporary equity, including noncontrolling interest240,372,461237,775,823235,883,906234,934,407234,600,000 
Equity
Equity, attributable to parent, including:(15,053,386)(14,778,112)(14,459,897)(14,169,529)(13,860,043) 
Accumulated deficit(15,054,017)(14,778,743)(14,460,528)(14,170,160)(13,860,674) 
Other undisclosed equity, attributable to parent631631631631631 
Total equity:(15,053,386)(14,778,112)(14,459,897)(14,169,529)(13,860,043) 
TOTAL LIABILITIES AND EQUITY:240,819,605238,324,586236,512,462235,806,409235,779,673 

Income Statement (P&L) (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Operating expenses (1,025,000)     
Other undisclosed operating income (loss)749,726(318,215)(290,368)(255,424)(307,189) 
Operating loss:(275,274)(318,215)(290,368)(255,424)(307,189) 
Nonoperating income
(Investment Income, Nonoperating)
2,596,6381,891,917949,499280,34545,367 
Income (loss) from continuing operations:2,321,3641,573,702659,13124,921(261,822) 
Income (loss) before gain (loss) on sale of properties:659,13124,921(261,822)
Net income (loss) available to common stockholders, diluted:2,321,3641,573,702659,13124,921(261,822) 

Comprehensive Income (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Net income (loss):2,321,3641,573,702659,13124,921(261,822) 
Comprehensive income (loss), net of tax, attributable to parent:2,321,3641,573,702659,13124,921(261,822) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: